NASDAQ:SPRY ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis $4.02 -0.05 (-1.23%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$4.01 0.00 (-0.12%) As of 10/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ARS Pharmaceuticals Stock (NASDAQ:SPRY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARS Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.81▼$4.0850-Day Range$3.93▼$6.3852-Week Range$3.81▼$13.15Volume2.33 million shsAverage Volume1.44 million shsMarket Capitalization$399.79 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingModerate Buy Company Overview ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product, neffy, is an epinephrine nasal spray designed to provide a needle-free alternative to injectable epinephrine for the emergency treatment of type I allergic reactions, including anaphylaxis. Neffy received approval from the U.S. Food and Drug Administration in 2024 for adults and children who meet the applicable weight requirements. The product is intended for use when rapid administration of epinephrine is needed and is designed to simplify delivery for patients, caregivers and health care professionals. The company has also pursued regulatory approvals and commercialization opportunities in European markets. ARS Pharmaceuticals is headquartered in San Mateo, California. The company is led by Chief Executive Officer Richard Low and continues to focus primarily on advancing its intranasal epinephrine platform and expanding access to emergency allergy treatment.AI Generated. May Contain Errors. Read More ARS Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreSPRY MarketRank™: 1.887890005285 of 5 starsARS Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 690th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingARS Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialARS Pharmaceuticals has a consensus price target of $25.00, representing about 521.9% upside from its current price of $4.02.Amount of Analyst CoverageARS Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about ARS Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($1.91) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ARS Pharmaceuticals is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARS Pharmaceuticals is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioARS Pharmaceuticals has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ARS Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted32.19% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in ARS Pharmaceuticals has recently decreased by 8.16%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldARS Pharmaceuticals does not currently pay a dividend.Dividend GrowthARS Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ARS Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders33.80% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ARS Pharmaceuticals' insider trading history. Receive SPRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRY Stock News HeadlinesHead to Head Analysis: ARS Pharmaceuticals (NASDAQ:SPRY) vs. Vanda Pharmaceuticals (NASDAQ:VNDA)October 8, 2026 | americanbankingnews.comSPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026October 5, 2026 | tmcnet.comElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.October 18 at 1:00 AM | Brownstone Research (Ad)ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYOctober 5, 2026 | prnewswire.comSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawOctober 5, 2026 | prnewswire.comARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitOctober 2, 2026 | prnewswire.comARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRYOctober 2, 2026 | globenewswire.comARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff RoleOctober 2, 2026 | globenewswire.comSee More Headlines SPRY Stock Analysis - Frequently Asked Questions How have SPRY shares performed this year? ARS Pharmaceuticals' stock was trading at $11.65 at the beginning of the year. Since then, SPRY shares have decreased by 65.5% and is now trading at $4.02. How were ARS Pharmaceuticals' earnings last quarter? ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.15. The business had revenue of $33.66 million for the quarter, compared to analyst estimates of $31.32 million. ARS Pharmaceuticals had a negative trailing twelve-month return on equity of 256.67% and a negative net margin of 184.24%. Read the conference call transcript. When did ARS Pharmaceuticals IPO? ARS Pharmaceuticals (SPRY) raised $207 million in an IPO on Friday, December 4th 2020. The company issued 11,500,000 shares at $17.00-$19.00 per share. Who are ARS Pharmaceuticals' major shareholders? Top institutional investors of ARS Pharmaceuticals include Norman Fields Gottscho Capital Management LLC (0.06%). Insiders that own company stock include Ra Capital Management, LP, Sarina Tanimoto, Richard E Lowenthal, Laura Shawver, Alexander A Fitzpatrick, Eric Karas, Brian Dorsey, Kathleen D Scott, Peter A Thompson, Justin Chakma and Brent L Saunders. View institutional ownership trends. How do I buy shares of ARS Pharmaceuticals? Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARS Pharmaceuticals investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), BioCryst Pharmaceuticals (BCRX), CrowdStrike (CRWD), Iovance Biotherapeutics (IOVA) and Barrick Mining (B). Company Calendar Last Earnings8/13/2026Today10/18/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SPRY's financial health is in the Red zone, according to TradeSmith. SPRY has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SPRY CIK1671858 Webars-pharma.com Phone(858) 771-9307FaxN/AEmployees200Year Founded2015Price Target and Rating Average Price Target for ARS Pharmaceuticals$25.00 High Price Target$30.00 Low Price Target$15.00 Potential Upside/Downside+521.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$171.30 million Net Margins-184.24% Pretax Margin-184.31% Return on Equity-256.67% Return on Assets-69.63% Debt Debt-to-Equity Ratio13.72 Current Ratio3.48 Quick Ratio3.28 Sales & Book Value Annual Sales$84.28 million Price / Sales4.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book3.47Miscellaneous Outstanding Shares99,450,000Free Float65,834,000Market Cap$399.79 million OptionableOptionable Beta0.85 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:SPRY) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThis link won't stay freeThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
